Vaccine Maker Halts Trial on mRNA Cancer Shot
The vaccine did not perform well in a clinical trial.
TL;DR
- BioNTech is terminating a clinical trial for an experimental mRNA cancer vaccine.
- The trial was a phase 2 study testing the vaccine in patients with colorectal cancer.
- Genentech is a partner in the development of the vaccine.
- A monitoring board recommended halting the trial due to survival imbalances.
- The trial continued past October 2025 because efficacy data were not yet mature or reliable.
- The primary endpoint could not be evaluated due to insufficient follow-up time.